Photo of Jeffrey Zwicker,  MD

Jeffrey Zwicker, MD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-9299
Fax: (617) 667-9922


jzwicker@bidmc.harvard.edu

Jeffrey Zwicker, MD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Medicine, Harvard Medical School
  • Asst Prof, Medicine, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Publications

Powered by Harvard Catalyst
  • Weinstock MJ, Uhlmann EJ, Zwicker JI. Intracranial hemorrhage in cancer patients treated with anticoagulation. Thromb Res 2016; 140 Suppl 1:S60-5. PubMed
  • Donato J, Campigotto F, Uhlmann EJ, Coletti E, Neuberg D, Weber GM, Zwicker JI. Intracranial hemorrhage in patients with brain metastases treated with therapeutic enoxaparin: a matched cohort study. Blood 2015. PubMed
  • Flaumenhaft R, Furie B, Zwicker JI. Therapeutic implications of protein disulfide isomerase inhibition in thrombotic disease. Arterioscler Thromb Vasc Biol 2014. PubMed
  • Arnason JE, Luptakova K, Rosenblatt J, Tzachanis D, Avigan D, Zwicker JI, Levine J, Kim M, Parker JA, Grant B, Joyce RM. Yttrium-90 ibritumomab tiuxetan followed by rituximab maintenance as treatment for patients with diffuse large B-cell lymphoma are not candidates for autologous stem cell transplant. Acta Haematol 2015; 133:347-53. PubMed
  • Zwicker JI, Bauer KA. How long is long enough? Extended anticoagulation for the treatment of cancer-associated deep vein thrombosis. J Clin Oncol 2014. PubMed
  • Zwicker JI, Rojan A, Campigotto F, Rehman N, Funches R, Connolly G, Webster J, Aggarwal A, Mobarek D, Faselis C, Neuberg D, Rickles FR, Wun T, Streiff MB, Khorana AA. Pattern of frequent but nontargeted pharmacologic thromboprophylaxis for hospitalized patients with cancer at academic medical centers: a prospective, cross-sectional, multicenter study. J Clin Oncol 2014; 32:1792-6. PubMed
  • Zwicker JI. Unconventional approaches to the prevention of cancer associated thrombosis. Thromb Res 2014; 133 Suppl 2:S44-8. PubMed
  • Carrier M, Khorana AA, Moretto P, Le Gal G, Karp R, Zwicker JI. Lack of evidence to support thromboprophylaxis in hospitalized medical patients with cancer. Am J Med 2014; 127:82-6.e1. PubMed
  • Zwicker JI, Liebman HA, Bauer KA, Caughey T, Campigotto F, Rosovsky R, Mantha S, Kessler CM, Eneman J, Raghavan V, Lenz HJ, Bullock A, Buchbinder E, Neuberg D, Furie B. Prediction and prevention of thromboembolic events with enoxaparin in cancer patients with elevated tissue factor-bearing microparticles: a randomized-controlled phase II trial (the Microtec study). British Journal of Haematology 2013; 160:530-7. PubMed
  • Khorana AA, Spyropoulos AC, Zwicker J, Lyman GH, Francis CW. Preventing VTE in Outpatients With Cancer. Chest 2012; 142:265-6; author reply 266-7. PubMed
  • Mantha S, Karp R, Raghavan V, Terrin N, Bauer KA, Zwicker JI. Assessing the risk of venous thromboembolic events in women taking progestin-only contraception: a meta-analysis. BMJ 2012; 345:e4944. PubMed
  • Zwicker JI, Lacroix R, Dignat-George F, Furie BC, Furie B. Measurement of platelet microparticles. Methods Mol Biol 2011; 788:127-39. PubMed
  • Zwicker JI, Trenor CC, Furie BC, Furie B. Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 2011; 31:728-33. PubMed
  • Zwicker JI, Liebman HA, Neuberg D, Lacroix R, Bauer KA, Furie BC, Furie B. Tumor-derived tissue factor-bearing microparticles are associated with venous thromboembolic events in malignancy. Clin Cancer Res 2009; 15:6830-40. PubMed
Hide